Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05850676

Disentangling the Role of Depression in Hypersomnia

Individuals who have disorders of hypersomnolence (excessive sleepiness) often report symptoms of depression. The goal of this study is to further understand of the relationship between depression and hypersomnia by examining mood-relevant domains of slow wave sleep and reward function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location status: Recruiting

Location contact

Nayeli Nunez-Cruz

CONTACT

[email protected]

215-746-3067

About this study

There are often challenges in the diagnosis of Idiopathic Hypersomnia (IH) in patients with comorbid psychiatric disorders, mood disorders in particular, who often report symptoms including excessive sleep duration and daytime somnolence. Further, 15-25% of patients with IH report significant depressive symptoms. When comparing these patients groups, studies have not found significant differences in depression scores, indicating the severity of depression cannot be reliably used to support diagnostic distinctions. These findings present significant challenges to the differential diagnosis of IH vs. Hypersomnia Associated with a Psychiatric Disorder (HAPD). Indeed, the diagnostic criteria of IH and HAPD overlap considerably, leaving clinicians to make the often challenging distinction of whether hypersomnia symptoms are temporally related to the course of the psychiatric disorder(s).

The difficulty in differentiating IH from HAPD has largely focused on subjective sleepiness, but some studies have utilized objective measures of sleepiness, in particular the MSLT, to compare these groups. Vgontzas and colleagues found that IH was associated with faster sleep onset on daytime nap opportunities compared to HAPD. Further, a systematic review and meta-analysis found that subjective hypersomnolence in patients with mood disorders was not associated with faster sleep latency on the MSLT compared to normative values, although there was significant heterogeneity. This discrepancy between subjective and objective hypersomnia can logically be explained by the presence of depressive symptoms. Depression is associated with cognitive distortions that lead individuals to interpret events from a more negative perspective, which leads to greater reporting of physical symptoms including pain and fatigue. An in-depth investigation of depression in patients with IH and HAPD may shed light on fundamental differences between these groups and improve diagnostic accuracy.

In understanding the relationship between depression and subjective hypersomnia it will be critical to look beyond subjective depressive symptoms because there will be de facto associations found due to the common use of self-report methods. Studies need to assess the neurobiological domains that underlie depression, both to utilize more objective methods and to understand the actual mechanisms driving these associations. A logical target in this regard would be the reward system, which is activated by any pleasurable stimuli and directs motivation to seek out these stimuli. Reward function is disrupted in individuals with depression, leading to two core features of anhedonia, i.e reduced capacity to experience pleasure and low motivation during waking hours. More specifically, patients with MDD demonstrate deficits in areas of reward function, namely reduced effort for rewards, discounting of monetary rewards, and impairments in reward learning. It also seems totoo reasonable to expect that reward dysfunction is also related to the experience of hypersomnia, although this has not been previously investigated. Interestingly, investigations have recently begun to examine the ways in which sleep disturbance may independently affect reward processes. Poor sleep at night can contribute to impaired reward function the next day.

A second depression-related system to investigate would be the sleep/wake system. Depression is known to be associated with abnormalities in sleep, in particular in slow wave sleep, the most restorative type of sleep. More specifically, the quantity of slow waves during sleep can be quantified as slow wave activity (SWA), with greater SWA associated with greater perceptions of feeling rested the next day. Depression is associated reduced SWA, which is thought the reflect deficient neuroplasticity. Patients with depression and hypersomnia have been found to exhibit reduced SWA compared to those without hypersomnia, suggesting a potential deficit in the restorative quality of sleep in these individuals. This suggests that the SWA deficiencies may be specifically related to subjective hypersomnia in depression. No studies have examined SWA dynamics in IH.

The overarching hypothesis is that greater severity of subjective, but not objective, hypersomnia in patients with IH and HAPD is related to a combination of disruption in slow wave sleep dynamics at night and deficits in reward processes. Demonstration of these effects could improve understanding of the nature of subjective vs. objective hypersomnia and lead to improve the differential diagnosis of hypersomnia disorders.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females between the age of 21 and 55
  • Meet DSM5 criteria for Idiopathic Hypersomnia or Hypersomnia Associated with a Psychiatry Disorder
  • Ability to read and speak English

Exclusion criteria

  • Unable or unwilling to provide informed consent
  • Untreated obstructive sleep apnea (apnea-hypopnea index /= 15 events/hr)
  • Meeting diagnostic criteria for narcolepsy
  • A clinically unstable medical condition as defined by a new diagnosis or change in medical management in the previous 2 months (e.g., pneumonia, thyroid disease, ventricular arrhythmias, cirrhosis, surgery, or recently diagnosed cancer) because these changes could impact daytime hypersomnia and confound results
  • Substance abuse/dependence, delirium, dementia, amnestic disorder, schizophrenia, and other psychotic disorders
  • Prominent current suicidal or homicidal ideation.
  • Unable to perform tests due to inability to communicate verbally, inability to read and write; less than a 5th grade reading level; visal, hearing, or cognitive impairment (e.g. previous head injury)
  • Use of medications or OTC products that might impact sleep

Treatment and study plan

sleep study

Diagnostic Test

Participants will spend two nights in the Penn Sleep Center

Primary outcomes

  1. Depression severity

    Time frame: One time at baseline

    Scores on the Hamilton Depression Inventory. Scores range from 0 to 52, with higher scores indiated more severe symptoms of depression.

Secondary outcomes

  1. Sleep slow wave activity

    Time frame: one night

    EEG activity in the delta frequency range during sleep

Study contacts

Contact information is provided by the study sponsor or research team.

Nayeli Nunez-Cruz

CONTACT

[email protected]

215-746-3067

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Collaborators

  • Jazz Pharmaceuticals

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 9, 2023
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.